Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
EY-cadherin CRISPR/Cas9 KO Plasmid (h): sc-401988
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EY-cadherin CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EY-cadherin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: EY-cadherin Antibody (YB.2): sc-81791
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EY-cadherin CRISPR/Cas9 KO Plasmid (h) | sc-401988 | 20 µg | $397.00 |
Overview
CDH18 encodes the human EY-cadherin, a classical cadherin family member that supports Ca²⁺-dependent cell–cell adhesion and contributes to tissue architecture by coupling adherens junctions to the actin cytoskeleton via catenin complexes. Through regulation of intercellular cohesion, polarity, and contact-dependent signaling, CDH18 can influence processes linked to epithelial and neuronal organization, including migration and boundary formation. Altered cadherin expression and junctional integrity are frequently associated with dysregulated differentiation and invasive behavior in disease-relevant models, making CDH18 a useful node for studying adhesion-driven phenotypes. CDH18 expression patterns and genetic or epigenetic perturbations have been investigated in contexts where cell identity and connectivity are disrupted, including cancer and neurodevelopmental disorders.
EY-cadherin CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CDH18 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CDH18 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CDH18 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EY-cadherin protein expression.
This CRISPR knockout system enables efficient generation of CDH18-deficient cell models for investigation of EY-cadherin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CDH18 exon(s) critical for EY-cadherin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CDH18 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EY-cadherin CRISPR/Cas9 KO Plasmid (h) and EY-cadherin CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CDH18 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EY-cadherin HDR Plasmid (h) and EY-cadherin HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CDH18 homology arms to support homology-directed repair at defined CDH18 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.